Vistagen Therapeutics (VTGN) Depreciation & Amortization (CF) (2010 - 2026)
Vistagen Therapeutics (VTGN) posted Depreciation & Amortization (CF) of $52000.0 for Q1 2026, down 3.7% sequentially from $54000.0 in Q4 2025, and up 30.0% YoY from $40000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $52000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 30.0% year-over-year to $52000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199000.0 (up 32.67% YoY) and the FY2026 annual result came in at $199000.0, up 32.67% from the prior year.
- Depreciation & Amortization (CF) retreated to $52000.0 in Q1 2026 per VTGN's latest filing, from $54000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $54000.0 in Q4 2025 and troughed at $30600.0 in Q4 2022.
- A 5-year average of $37875.0 and a median of $33900.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) slipped 29.98% in 2022, then surged 43.24% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $30600.0 in 2022, then grew by 1.31% to $31000.0 in 2023, then increased by 25.81% to $39000.0 in 2024, then surged by 38.46% to $54000.0 in 2025, then declined by 3.7% to $52000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $52000.0, $54000.0, and $53000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | 52,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,000.00 |
| Mar 31, 2026 | 52,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 40,000.00 |
| Mar 31, 2025 | 40,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Dec 31, 2024 | 39,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Dec 31, 2023 | 31,000.00 |